Forecast

There is no analyst data available for this company.

News Go to news feed

Clinuvel reports tenth profitable year and strong balance sheet, stock falls 12% pre-market

Clinuvel extended its profit streak, posting the tenth profitable year in a row; revenue exceeded AUD 100m for the second consecutive year, gross margin was 83% and cash and equivalents rose to AUD 252m. Despite strong fundamentals, the stock fell 12.35% pre-market after weakness in US sales of SCENESSE due to competing samples and the announced planned relocation of the headquarters and delisting from the ASX in favor of a Nasdaq listing. The company remains debt-free, continues to invest in R&D and expects ongoing annual spending of around AUD 55m in coming years, while key development programs (vitiligo, NEURACTHEL) still require trials and regulatory decisions. » More on de.investing.com
Expansion costs push Clinuvel profit down 26% despite record revenue

Clinuvel reports a 4% rise in revenue for H1 FY2026 to A$36.93m — the strongest first half in the company's history — while net profit fell 26% to A$10.4m due to a 22% increase in expansion costs. Operating expenses rose particularly in personnel, clinical development and sales, while cash reserves of A$233m enable a self-funded expansion. Key catalysts are regulatory decisions, first topline results from the vitiligo Phase‑III study CUV105 in H2 2026 and completion of the R&D centre in Singapore; the vitiligo programme represents the largest growth opportunity. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2025, Clinuvel Pharmaceuticals has already paid €0.0281 in dividends. The last payout was in September 2025.

Financials

In the last quarter, Clinuvel Pharmaceuticals had revenue of €34.58M and net profit of €14.22M

(EUR)	Jun 2026	YoY
Revenue	34.58M	-
Gross profit	11.98M	-
Net profit	14.22M	-
EBITDA	17.61M	-

Fundamentals

Metric	Value
Market capitalization	€264.08M
Number of shares	50.41M
52-week high/low	€8.34 - €5.16
Dividend yield	0.52%
Dividends TTM	€0.0281
Beta	0.57
P/E ratio	12.46
PEG ratio	-2.24
P/B ratio	1.69
P/S ratio	4.54

Company profile

Clinuvel Pharmaceuticals Limited, ein biopharmazeutisches Unternehmen, konzentriert sich auf die Entwicklung und Vermarktung von Behandlungen für Patienten mit genetischen, metabolischen und lebensbedrohlichen Störungen in Australien, Europa, den Vereinigten Staaten, der Schweiz und international. Der führende Medikamentenkandidat ist SCENESSE, ein systemisches photoprotektives Medikament zur Prävention von Phototoxizität bei erwachsenen Patienten mit erythropoetischer Protoporphyrie (EPP). Zu den Pipeline-Produkten des Unternehmens gehören CUV9900, ein Analogon des Alpha-Melanozyten-stimulierenden Hormons, Parvysmelanotid (VLRX001), das eine erhöhte und verlängerte Zellaktivität hervorruft, und PRÉNUMBRA, eine flüssige injizierbare Formulierung von Afamelanotid. Clinuvel Pharmaceuticals Limited hat eine Kooperationsvereinbarung mit HK Winhealth Pharma Group Co. Limited zur Behandlung von EPP-Patienten mit SCENESSE im Rahmen eines benannten Patientenprogramms in der Volksrepublik China. Das Unternehmen wurde 1987 gegründet und hat seinen Hauptsitz in Melbourne, Australien.

Name	Clinuvel Pharmaceuticals
CEO	Philippe Jacques Wolgen
Headquarters	Melbourne, vic Australia
Website	clinuvel.com
Sector	Health Care
Industry	Pharmaceuticals
IPO	02/11/2001
Employees	16